Numerous studies on treatment for idiopathic pulmonary fibrosis (IPF) focus on inhibiting the TGF-β pathway, including antagonizing TGF-β, inhibiting Smad2/3 phosphorylation, and activating Smad7 [39]. This evidence concerns the gene SMAD7 and pulmonary fibrosis.